On September 9, 2024 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea" or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, reported that Oren Gilad Ph.D, President and Chief Executive Officer, will deliver an in-person presentation at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY (Press release, Aprea, SEP 9, 2024, View Source [SID1234646421]). Details are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 26th Annual Global Investment Conference
Date: September 10, 2024
Time: 9am ET
Location: Holmes II, Lotte New York Palace Hotel
Webcast: click here
The webcast will also be archived on Aprea’s corporate website.
Management are also available for one-on-one meetings with institutional investors. To request a meeting, please contact your conference representative.